OSAM
BCLI

O'Shaughnessy Asset Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

O'Shaughnessy Asset Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-9
Closed -$1K – 2571
2021
Q1 		$1K Sell
9
-3
-25% -$227 ﹤0.01% 2136
2020
Q4 		$1K Buy
12
+9
+300% +$1.23K ﹤0.01% 1893
2020
Q3 		$1K Hold
3
– – ﹤0.01% 1699
2020
Q2 		$1K Buy
+3
New +$323 ﹤0.01% 1564

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

O'Shaughnessy Asset Management's BCLI Position: Q2 2021 in Review

O'Shaughnessy Asset Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2021, closing a stake of 9 shares — an estimated $1K sold.

O'Shaughnessy Asset Management first reported a position in BCLI in Q2 2020 and held it in 4 quarters. The position peaked at $1K in Q1 2021. 57 funds tracked by Wall St. Rank hold BCLI as of Q2 2021.

  • O'Shaughnessy Asset Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2021 after selling out during the quarter.
  • O'Shaughnessy Asset Management sold 9 BRAINSTORM CELL THERAPUTC shares in Q2 2021, an estimated $1K.
  • O'Shaughnessy Asset Management first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2020 and held it in 4 quarters.
  • O'Shaughnessy Asset Management's BRAINSTORM CELL THERAPUTC position peaked at $1K in Q1 2021.
  • 57 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2021.

Based on O'Shaughnessy Asset Management's 13F filing for Q2 2021, filed 9 Aug 2021.